Doç.Dr. KLARA DALVA

Kişisel Bilgiler

İş Telefonu: +90 508 273 9
E-posta: dalva@ankara.edu.tr
Web: https://avesis.ankara.edu.tr/dalva

Uluslararası Araştırmacı ID'leri
ORCID: 0000-0001-6917-6870
ScopusID: 6601955440
Yoksis Araştırmacı ID: 180955

Eğitim Bilgileri

Tıpta Uzmanlık, Diğer (Kurumlar,hastaneler Vb.), Hastaneler, Ankara Türkiye Yüksek İhtisas Eğitim Ve Araştırma Hastanesi, Türkiye 1987 - 1990
Lisans, Ege Üniversitesi, Ege Tıp Fakültesi, Ege Tıp Pr., Türkiye 1978 - 1984

Yabancı Diller

İngilizce, B2 Orta Üstü

Araştırma Alanları

Sağlık Bilimleri

Verdiği Dersler

tez çalışması, Yüksek Lisans, 2018 - 2019
Tıbbi laboratuvar teknikleri Klinik LAboratuvar uygulamaları II, Ön Lisans, 2018 - 2019
seminer, Yüksek Lisans, 2018 - 2019
TIBBİ LABORATUVAR TEKNİKLERİ HEMATOLOJİ 1, Ön Lisans, 2018 - 2019
tıbbi LAboratuvar Teknikler Hematoloji II, Ön Lisans, 2017 - 2018
AKIM SİTOMETRİ (UYGULAMA), Yüksek Lisans, 2017 - 2018, 2016 - 2017, 2015 - 2016
AKIM SİTOMETRİ (TEORİK), Yüksek Lisans, 2017 - 2018, 2016 - 2017, 2015 - 2016
Tıbbi LAboratuvar Tekniklari Klinik LAboratuvar uygulamaları II, Ön Lisans, 2017 - 2018
TIBBİ LABORATUVAR TEKNİKLERİ HEMATOLOJİ 1, Lisans, 2016 - 2017, 2015 - 2016, 2014 - 2015
Akım sitometri- Teorik, Yüksek Lisans, 2014 - 2015
Akım Sitometri- uygulama , Yüksek Lisans, 2014 - 2015
Tıbbi laboratuvar teknikleri -klinik laboratuvar uygulamaları 1, Ön Lisans, 2014 - 2015

Yönetilen Tezler

DALVA K., Hematopoietik kök hücre nakli için toplanan aferez ürünlerinde CD34+ hücrelerin mutlak sayımında "single

platform" ISHAGE Protokolü ile volümetrik ölçümlerin karşılaştırılması, Yüksek Lisans, N.KOZAN(Öğrenci), 2019

SCI, SSCI ve AHCI İndekslerine Giren Dergilerde Yayınlanan Makaleler

I. **In vivo and in vitro effects of cord blood hematopoietic stem and progenitor cell (HSPC) expansion using valproic acid and/or nicotinamide**
Gencer E. B., Akin H. Y., TOPRAK S. K., Turasan E., Yousefzadeh M., Yurdakul-Mesutoglu P., Cagan M., SEVAL M. M., Katlan D. C., DALVA K., et al.
Current Research in Translational Medicine, cilt.72, sa.3, 2024 (SCI-Expanded)

II. **Post-induction undetectable flow minimal residual disease ameliorates the high risk determined by FISH among newly diagnosed multiple myeloma**
CENGİZ SEVAL G., DALVA K., Bakanay S. M., Soydan E., İLHAN O., BEKSAÇ M., SÖNMEZ G. M.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023 (SCI-Expanded)

III. **A Novel Hypothesis: Certain KIR/Cognate Ligand Containing Genotypes Differ in Frequency Among Patients With Myeloma and Have an Effect on Age of Disease Onset**
BEKSAÇ M., Akin H. Y., CENGİZ SEVAL G., Yurdakul Mesutoglu P., Anliacik R. G., Anliacik E., Gurman G., Karaagaoglu E., DALVA K.
Clinical Lymphoma, Myeloma and Leukemia, cilt.23, sa.5, ss.394, 2023 (SCI-Expanded)

IV. **Role of large unstained cells in predicting successful stem cell collection in autologous stem cell transplantation**
Merter M., Sahin U., Uysal S., DALVA K., YÜKSEL M.
Transfusion and Apheresis Science, cilt.62, sa.1, 2023 (SCI-Expanded)

V. **Two birds with one stone: a Bruton's tyrosine kinase inhibitor in a patient with rheumatoid arthritis and 17p+chronic lymphocytic leukaemia**
Sahin Eroglu D., DALVA K., Azap A., Kutlay N., Ates A., Yuksel M.
SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, cilt.52, sa.6, ss.703-704, 2023 (SCI-Expanded)

VI. **Effect of CD34⁺ Total/Myeloid CD34⁺ Cell Progenitors and B-Lymphoid Progenitors Within the Bone Marrow Grafts on the Hematopoietic Recovery After Hematopoietic Stem Cell Transplantation.**
DALVA K., Haskologlu S., DALVA AYDEMİR S., ÖZ M. D., ÖZTÜRK BİRGE A., Ipek S., Demir H. A., ERTEM M., Ilhan O., GÜRMAN G.
Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation, cilt.20, sa.10, ss.937-944, 2022 (SCI-Expanded)

VII. **A model integrating Killer Immunoglobulin-like Receptor (KIR) haplotypes for risk prediction of COVID-19 clinical disease severity**
BEKSAÇ M., Akin H. Y., Gencer-Oncul E. B., Yousefzadeh M., CENGİZ SEVAL G., GÜLTEN E., AKDEMİR KALKAN İ., ÇINAR G., Memikoglu O., Karaagaoglu E., et al.
Immunogenetics, cilt.73, sa.6, ss.449-458, 2021 (SCI-Expanded)

VIII. **Significance of inhibitory maternal killer-cell immunoglobulin-like receptor (KIR) and fetal KIR ligand genotype combinations in placenta related obstetric complications**
Orgul G., DALVA K., DALVA AYDEMİR S., Alniacik R. G., DÖNMEZ H. G., Cakar A. N., BEKSAÇ M., BEKSAÇ M. S.
JOURNAL OF REPRODUCTIVE IMMUNOLOGY, cilt.148, 2021 (SCI-Expanded)

IX. **Post-Induction Undetectable Minimal Residual Disease at 10 (-5) Sensitivity Level within Marrow and/or Stem Cell Graft Overrides Cytogenetic High Risk**
Seval G., DALVA K., Oz D., Bakanay S. M., Soydan E., GÜRMAN G., Ilhan O., BEKSAÇ M.
BLOOD, cilt.138, 2021 (SCI-Expanded)

X. **Leukemic stem cells shall be searched in the bone marrow before "tyrosine kinase inhibitor-discontinuation" in chronic myeloid leukemia**
İLHAN O., Narli Ozdemir Z., DALVA K., ARSLAN A., Okay Ozgeyik M., Ipek S., SAYDAM G., HAZNEDAROĞLU İ. C.
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, cilt.43, sa.5, ss.1110-1116, 2021 (SCI-Expanded)

XI. **Single-Center Study of 72 Patients with Severe Combined Immunodeficiency: Clinical and Laboratory**

Features and Outcomes
BAYRAM Ö., Haskologlu S., Bayrakoglu D., Bal S. K., Islamoglu C., Cipe F. E., KENDİRLİ T., Kursun N., GÜNER Ş. N., YILDIRAN A., et al.
JOURNAL OF CLINICAL IMMUNOLOGY, cilt.41, sa.7, ss.1563-1573, 2021 (SCI-Expanded)

XII. **Long-Term Outcomes of Tamoxifen Citrate Therapy and Histo- And Immunopathological Properties in Riedel Thyroiditis**
GÖKÇAY CANPOLAT A., Cinel M., Dizbay Sak S., Taskaldiran I., KORKMAZ H., DEMİR Ö., ERSOY R., DAĞDELEN S., Berker D., DALVA K., et al.
European Thyroid Journal, cilt.10, sa.3, ss.248-256, 2021 (SCI-Expanded)

XIII. **Pleural Involvement Upon Relapse of Myeloma Responding to Daratumumab Plus Carfilzomib: A Case Presentation and Literature Review**
Uslu A., CENGİZ SEVAL G., Merter M., DALVA K., BEKSAÇ M.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, cilt.21, sa.3, 2021 (SCI-Expanded)

XIV. **Highlighting the Prognostic Importance of Measurable Residual Disease Among Acute Myeloid Leukemia Risk Factors**
Ozdemir Z. N., Sahin U., DALVA K., BALTACI M. A., Uslu A., Ozturk C., CENGİZ SEVAL G., TOPRAK S. K., Yuksel M., TOPÇUOĞLU P., et al.
TURKISH JOURNAL OF HEMATOLOGY, cilt.38, sa.2, ss.111-118, 2021 (SCI-Expanded)

XV. **A Bottom-Up Proteomic Approach in Bone Marrow Plasma Cells of New-ly Diagnosed Multiple Myeloma Patients**
Ayhan B., Turan S. K., Barkan N. P., DALVA K., BEKSAÇ M., Demiralp D. O.
CURRENT PROTEOMICS, cilt.18, sa.5, ss.730-741, 2021 (SCI-Expanded)

XVI. **Transferability and curability of allergic disease by allogeneic hematopoietic stem cell transplantation.**
Mungan D., GÜRMAN G., Misirligil Z., TOPRAK S. K., DALVA K., TOPÇUOĞLU P., Akdis M., Akdis C.
Allergy, cilt.75, sa.9, ss.2392-2394, 2020 (SCI-Expanded)

XVII. **A CD34+Cell Enrichment Protocol of Hematopoietic Stem Cells in a Well-Established Quality Management System**
Kılıç P., Bay M., Yildirim Y., Coskun Ö., Seker Ş., Baydın P., Ulker O. L., Parmaksız M., Çubukçuoğlu Deniz G., Yılmazer Aktuna A., et al.
CELLS TISSUES ORGANS, cilt.207, sa.1, ss.15-20, 2019 (SCI-Expanded)

XVIII. **THE EFFECT OF PREDICTED INDIRECTLY RECOGNIZABLE HLA EPITOPES PRESENTED BY HLA-CLASS II MOLECULES ON 1 ANTIGEN/ALELLE MISMATCHED UNRELATED HSCT: A SINGLE CENTER EXPERIENCE**
DALVA K., CENGİZ SEVAL G., Oz D., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., Anliacik E., Altan H., Anliacik R., et al.
HLA, cilt.93, sa.5, ss.368-369, 2019 (SCI-Expanded)

XIX. **Comparison of the methods evaluating post thawing viability of peripheral blood stem cell graft**
Varan H. D., Bay M., Ozturk A., DALVA K., İLHAN O.
TRANSFUSION AND APHERESIS SCIENCE, cilt.58, sa.2, ss.192-195, 2019 (SCI-Expanded)

XX. **Hematology Laboratory Survey Reply**
Kozanoglu I., Patiroglu T., Dalva K., Demirel G. Y., Soysal T., Demir M.
TURKISH JOURNAL OF HEMATOLOGY, cilt.35, sa.4, ss.304, 2018 (SCI-Expanded)

XXI. **Results of the Hematology Laboratory Survey: What has Changed in Eight Years?**
KOZANOĞLU İ., Patiroglu T., DALVA K., YANIKKAYA DEMİREL G., Soysal T., Demir M.
TURKISH JOURNAL OF HEMATOLOGY, cilt.35, sa.3, ss.215-216, 2018 (SCI-Expanded)

XXII. **Donor-recipient killer immunoglobulin like receptor (KIR) genotype matching has a protective effect on chronic graft versus host disease and relapse incidence following HLA-identical sibling hematopoietic stem cell transplantation**
Sahin U., DALVA K., Gungor F., Ustun C., BEKSAÇ M.
ANNALS OF HEMATOLOGY, cilt.97, sa.6, ss.1027-1039, 2018 (SCI-Expanded)

XXIII. **Differential gene expression profiling of human adipose stem cells differentiating into smooth muscle-like cells by TGF beta 1/BMP4**
Elçin A. E., Parmaksız M., Dogan A., Seker Ş., Durkut S., Dalva K., Elçin Y. M.
EXPERIMENTAL CELL RESEARCH, cilt.352, sa.2, ss.207-217, 2017 (SCI-Expanded)

XXIV. **The effect of age on peripheral stem cell mobilization in healthy donors, single center experience**
Ozen M., Gunduz M., TOPÇUOĞLU P., TOPRAK S. K., DALVA K., GÜRMAN G., İLHAN O.
JOURNAL OF CLINICAL APHERESIS, cilt.32, sa.1, ss.16-20, 2017 (SCI-Expanded)

XXV. **Flow Cytometric Aldehyde Dehydrogenase Assay Enables a Fast and Accurate Human Umbilical Cord Blood Hematopoietic Stem Cell Assessment**
Gencer E. B., Yurdakul P., DALVA K., BEKSAÇ M.
TURKISH JOURNAL OF HEMATOLOGY, cilt.34, sa.4, ss.314-320, 2017 (SCI-Expanded)

XXVI. **Can Burkitt's Lymphoma and Hodgkin's Lymphoma occur in siblings simultaneously?**
Kaymak-Cihan M., Kandemir O., DALVA K., Sari N., Kurucu N., Ergurhan-Ilhan I.
TURKISH JOURNAL OF PEDIATRICS, cilt.57, sa.5, ss.536-540, 2015 (SCI-Expanded)

XXVII. **Impact of "Killer Immunoglobulin-Like Receptor/Ligand" Genotypes on Outcome following Surgery among Patients with Colorectal Cancer: Activating KIRs Are Associated with Long-Term Disease Free Survival**
Beksac K., BEKSAÇ M., DALVA K., Karaagaoglu E., TIRNAKSIZ M. B.
PLOS ONE, cilt.10, sa.7, 2015 (SCI-Expanded)

XXVIII. **The impact of donor age and sex on the nucleated cell count and CD34 count in healthy bone marrow donors**
İNCE E., İLERİ D. T., DOĞU E. F., Ates C., ÇAKMAKLI H. F., DALVA K., İKİNCİOĞULLARI K. A., Uysal Z., ERTEM M.
PEDIATRIC TRANSPLANTATION, cilt.19, sa.4, ss.385-390, 2015 (SCI-Expanded)

XXIX. **Comparison of Filgrastim and Lenograstim in Pediatric Solid Tumors**
Sari N., DALVA K., Ilhan I. E.
PEDIATRIC HEMATOLOGY AND ONCOLOGY, cilt.30, sa.7, ss.655-661, 2013 (SCI-Expanded)

XXX. **Effects of Preoperative Short Term Use of Atorvastatin on Endothelial Progenitor Cells after Coronary Surgery: A Randomized, Controlled Trial**
BARAN Ç., Durdu S., DALVA K., Zaim C., Dogan A., OCAKOĞLU G., GÜRMAN G., ARSLAN Ö., AKAR A. R.
STEM CELL REVIEWS AND REPORTS, cilt.8, sa.3, ss.963-971, 2012 (SCI-Expanded)

XXXI. **Stem Cell Therapy in Spinal Cord Injury: In Vivo and Postmortem Tracking of Bone Marrow Mononuclear or Mesenchymal Stem Cells**
ÖZDEMİR M., ATTAR A., KUZU I., Ayten M., Ozgencil E., BOZKURT M., DALVA K., ÇETİNKAYA F. D., Kilic E., Sancak T., et al.
STEM CELL REVIEWS AND REPORTS, cilt.8, sa.3, ss.953-962, 2012 (SCI-Expanded)

XXXII. **HLA-haploidentical transplantations for primary immunodeficiencies: A single-center experience**
Cipe F. E., DOĞU E. F., Aytekin C., Yuksek M., KENDİRLİ T., Yildiran A., Bozdogan G., Karatas D., Reisli I., DALVA K., et al.
PEDIATRIC TRANSPLANTATION, cilt.16, sa.5, ss.451-457, 2012 (SCI-Expanded)

XXXIII. **Report from the European myeloma network on interphase FISH in multiple myeloma and related disorders**
Ross F. M., Avet-Loiseau H., Ameye G., Gutiérrez N. C., Liebisch P., O'Connor S., DALVA K., Fabris S., Testi A. M., Jarosova M., et al.
Haematologica, cilt.97, sa.8, ss.1272-1277, 2012 (SCI-Expanded)

XXXIV. **Flow Cytometric Evaluation of Cell Cycle Regulators (Cyclins and Cyclin-Dependent Kinase Inhibitors) Expressed on Bone Marrow Cells in Patients with Chronic Myeloid Leukemia and Multiple Myeloma**
TOPRAK S. K., Dalva K., Cakar M. K., Kursun N., BEKSAÇ M.
TURKISH JOURNAL OF HEMATOLOGY, cilt.29, sa.1, ss.17-27, 2012 (SCI-Expanded)

XXXV. **Myeloma as a second malignancy following AML: Is a second allo equivalent to auto?**
Bakanay S. M., Serbest E., DALVA K., KUZU I., BEKSAÇ M.

Case Reports in Medicine, cilt.2012, 2012 (SCI-Expanded)

XXXVI. **The Shaping of Modern Human Immune Systems by Multiregional Admixture with Archaic Humans**
Abi-Rached L., Jobin M. J., Kulkarni S., McWhinnie A., DALVA K., Gragert L., Babrzadeh F., Gharizadeh B., Luo M., Plummer F. A., et al.
SCIENCE, cilt.334, sa.6052, ss.89-94, 2011 (SCI-Expanded)

XXXVII. **Follow-up of ADAMTS13 enzyme and its relationship with clinical events after allogeneic hematopoietic stem cell transplantation**
CİVRİZ BOZDAĞ S., Gunaltay S., DALVA K., ÖZCAN M.
BLOOD COAGULATION & FIBRINOLYSIS, cilt.20, sa.3, ss.165-169, 2009 (SCI-Expanded)

XXXVIII. **The impact of methylenetetrahydrofolate reductase (MTHFR) C677T gene polymorphism on transplant-related variables after allogeneic hematopoietic cell transplantation in patients receiving MTX as GVHD prophylaxis**
Soydan E., Topcuoglu P., Dalva K., Arat M.
BONE MARROW TRANSPLANTATION, cilt.42, sa.6, ss.429-430, 2008 (SCI-Expanded)

XXXIX. **T-helper-1 (Th1) and Th2 cytokines after allogeneic hematopoietic stem cell transplantation (allo-HSCT)**
TOPÇUOĞLU P., Bakanay Ş. M., DALVA K., Arat M., BEKSAÇ M., ÖZCAN M.
Turkish Journal of Hematology, cilt.25, sa.1, ss.24-35, 2008 (SCI-Expanded)

XL. **Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders**
Rawstron A. C., Orfao A., BEKSAÇ M., Bezdickova L., Brooimans R. A., Bumbea H., DALVA K., Fuhler G., Gratama J., Hose D., et al.
HAEMATOLOGICA, cilt.93, sa.3, ss.431-438, 2008 (SCI-Expanded)

XLI. **High CD95 expression of BAL lymphocytes predicts chronic course in patients with sarcoidosis**
Ozdemir Ö., ÇELİK G., Dalva K., Ulger F., ELHAN A. H., BEKSAÇ M.
RESPIROLOGY, cilt.12, sa.6, ss.869-873, 2007 (SCI-Expanded)

XLII. **Impact of harvest product volume in erythrocyte depletion of allogeneic or autologous bone marrow using COBE spectra**
Soydan E., Ayyildiz E., Dalva K., Topcuoglu P., Tol M., Arslan O., Ilhan O., Arat M.
TRANSFUSION AND APHERESIS SCIENCE, cilt.36, sa.3, ss.269-273, 2007 (SCI-Expanded)

XLIII. **How to calculate the quantity of CD34+ cells infused? A single center cohort study based on actual, ideal or adjusted ideal body weight**
Topcuoglu P., Soydan E. A., Ekiz F., Ayyildiz E., Dalva K., Ozcan M., Arslan O., Arat M., Han O.
TRANSFUSION AND APHERESIS SCIENCE, cilt.36, sa.3, ss.275-280, 2007 (SCI-Expanded)

XLIV. **Effects of plasma nitric oxide levels on platelet activation in single donor apheresis and random donor concentrates**
Buyukkagnici D. I., Ilhan O., Kavas G. O., Arslan O., Arat M., Dalva K., Ayyildiz E.
TRANSFUSION AND APHERESIS SCIENCE, cilt.36, sa.1, ss.73-78, 2007 (SCI-Expanded)

XLV. **The effect of extracorporeal photoimmunotherapy (ECP) on serum TNF-a level in chronic graft versus host disease (GvHD)**
Ayyildiz E., Arslan O., Topcuoglu P., Arat M., Dalva K., Soydan E. A., Tol M., Ilhan O.
TRANSFUSION AND APHERESIS SCIENCE, cilt.36, sa.1, ss.79-85, 2007 (SCI-Expanded)

XLVI. **Screening for hemochromatosis in Turkey**
Bozkaya H., Bektas M., Metin O., Erkan O., Ibrahimoglu D., Dalva K., Akbiyik F., Gurel S., Bozdayi A., Akay C., et al.
DIGESTIVE DISEASES AND SCIENCES, cilt.49, sa.3, ss.444-449, 2004 (SCI-Expanded)

XLVII. **The impact of granulocyte colony stimulating factor at content of donor lymphocytes collected for cellular immunotherapy**
Arat M., Arslan O., GÜRMAN G., Dalva K., Ozcan M., Ugur A., Ilhan O.
TRANSFUSION AND APHERESIS SCIENCE, cilt.30, sa.1, ss.9-15, 2004 (SCI-Expanded)

XLVIII. **Administration of granulocyte-colony-stimulating factor for allogeneic hematopoietic cell collection may induce the tissue factor-dependent pathway in healthy donors**

Topcuoglu P., Arat M., Dalva K., Ozcan M.
BONE MARROW TRANSPLANTATION, cilt.33, sa.2, ss.171-176, 2004 (SCI-Expanded)

XLIX. **The detection of flow cytometric G-CSF receptor expression and it's effect on therapy in acute myeloid leukemia**
Kutlay S., BEKSAÇ M., Dalva K., Ilhan O., Koc H., Akan H., Ozcan M.
LEUKEMIA & LYMPHOMA, cilt.44, sa.5, ss.791-795, 2003 (SCI-Expanded)

L. **Extramedullary presentation of biclonal IgGκ and IgAκ multiple myeloma**
Alanoğlu G., Özet G., DALVA K., KUZU I., Erekul S., İLHAN O., BEKSAÇ M.
Turkish Journal of Haematology, cilt.19, sa.3, ss.421-425, 2002 (SCI-Expanded)

LI. **Monitoring of peripheral blood CD34+cell counts on the first day of apheresis is highly predictive for efficient CD34+cell yield**
Demirer T., Ilhan O., Ayli M., Arat M., Dagli M., Ozcan M., Haznedar R., Genc Y., Fen T., Ayyildiz E., et al.
THERAPEUTIC APHERESIS, cilt.6, sa.5, ss.384-389, 2002 (SCI-Expanded)

LII. **In vivo use of all-trans retinoic acid prior to induction chemotherapy improves complete remission rate and increases rhodamine 123 uptake in patients with de novo acute myeloid leukemia**
Ustun C., BEKSAÇ M., Dalva K., Koc H., Konuk N., Ilhan O., Ozcan M., Topcuoglu P., Sertkaya D., Hayran M.
MEDICAL ONCOLOGY, cilt.19, sa.1, ss.59-67, 2002 (SCI-Expanded)

LIII. **Probability of finding a HLA identical related bone marrow donor approaches 1:2 in a Turkish registry. Roles of donor bone marrow & cord blood registry and extended family search**
DALVA K., Meriç S., GÜVEN N. M., Ikizunal Y., BEKSAÇ M.
European Journal of Immunogenetics, cilt.28, sa.2, ss.358, 2001 (SCI-Expanded)

LIV. **CD41+ and CD42+ hematopoietic progenitor cells may predict platelet engraftment after allogeneic peripheral blood stem cell transplantation**
DEMİRER T., Ilhan O., Arat M., YAVUZ Y., ÖZCAN M. E., DALVA K., ÇELEBİ H., Beksaç M., Akan H., Gürman G., et al.
Journal of Clinical Apheresis, cilt.16, sa.2, ss.67-73, 2001 (SCI-Expanded)

LV. **Prenatal diagnosis of intrauterine cytomegalovirus infection in a fetus with non-immune hydrops fetalis**
Beksac M., Saygan-Karamursel B., Ustacelebi S., Altinok G., Dalva K., Erdinc S., Balci S.
ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, cilt.80, sa.8, ss.762-765, 2001 (SCI-Expanded)

LVI. **Effects of combined conventional and modified ultrafiltration in adult patients**
Kiziltepe U., Uysalel A., Corapcioglu T., Dalva K., Akan H., Akalin H.
ANNALS OF THORACIC SURGERY, cilt.71, sa.2, ss.684-693, 2001 (SCI-Expanded)

LVII. **The effect of G-CSF on lymphocyte subsets and CD34+cells in allogeneic stem cell transplantation**
GÜRMAN G., Dilek I., Arslan O., Arat M., BEKSAÇ M., Ilhan O., Ozcan M., Akan H., Dalva K., Konuk N., et al.
TRANSFUSION AND APHERESIS SCIENCE, cilt.24, sa.1, ss.23-28, 2001 (SCI-Expanded)

LVIII. **CD41+and CD42+hematopoietic progenitor cells may predict platelet engraftment after allogeneic peripheral blood stem cell transplantation**
Demirer T., Ilhan O., Arat M., Genc Y., Ozcan M., Dalva K., Celebi H., BEKSAÇ M., Akan H., GÜRMAN G., et al.
JOURNAL OF CLINICAL APHERESIS, cilt.16, sa.2, ss.67-73, 2001 (SCI-Expanded)

LIX. **Beneficial effects of iloprost during experimentally induced hemorrhagic shock**
Katircioglu S., Ulus A., Gokce P., Apaydin N., Ayaz S., Dalva K., Koc B., Atalay F.
PANMINERVA MEDICA, cilt.42, sa.2, ss.109-117, 2000 (SCI-Expanded)

LX. **Thrombopoietic cytokines in patients with iron deficiency anemia with or without thrombocytosis**
Akan H., Guven N., Aydogdu I., Arat M., BEKSAÇ M., Dalva K.
ACTA HAEMATOLOGICA, cilt.103, sa.3, ss.152-156, 2000 (SCI-Expanded)

LXI. **Soluble adhesion molecules (sICAM-1, sL-Selectin, sE-Selectin, sCD44) in healthy allogenic peripheral stem-cell donors primed with recombinant C-CSF**
Arslan O., Akan H., Arat M., Dalva K., Ozcan M., GÜRMAN G., Ilhan O., Konuk N., BEKSAÇ M., Uysal A., et al.
CYTOTHERAPY, cilt.2, sa.4, ss.259-265, 2000 (SCI-Expanded)

LXII. **Analysis of tissue factor (TF) expression on leukemic cells by flow cytometry: Correlation with tissue factor activity and clinical parameters**

Kilic S., Ozcan M., Dalva K., BEKSAÇ M., Koc H.
THROMBOSIS AND HAEMOSTASIS, ss.763, 1999 (SCI-Expanded)

LXIII. **THE BENEFICIAL-EFFECTS OF AMINOPHYLLINE ADMINISTRATION ON HEPARIN REVERSAL WITH PROTAMINE**
KATIRCIOGLU S., KUCUKAKSU D., BOZDAYI M., DALVA K., MAVITAS B., ZORLUTUNA Y., TASDEMIR O., BAYAZIT K.
SURGERY TODAY-THE JAPANESE JOURNAL OF SURGERY, cilt.24, sa.2, ss.99-102, 1994 (SCI-Expanded)

LXIV. **SERUM LEVELS OF CYTOKINES IN CHRONIC VIRAL LIVER-DISEASE**
DOLAR M. E., BAYSAL C., DALVA K., CANER M., SAHIN B.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, cilt.5, sa.11, ss.947-950, 1993 (SCI-Expanded)

LXV. **SOLUBLE CD23 AND INTERLEUKIN-2 RECEPTOR LEVELS IN RENAL-ALLOGRAFT RECIPIENTS**
BEKSAÇ M., DALVA K., GONENC F., DALVA I., GARIBOGLU S., BATUR N., CETIN S.
TRANSPLANTATION PROCEEDINGS, cilt.25, sa.2, ss.2145-2147, 1993 (SCI-Expanded)

Diğer Dergilerde Yayınlanan Makaleler

I. **The Influence of ATG on the Outcomes of Patients With AML at the Time of Unrelated Donor Transplantation**
CENGİZ SEVAL G., KIRCALI E., CİVRİZ BOZDAĞ S., TOPÇUOĞLU P., YÜKSEL M., DALVA K., ARSLAN Ö., ÖZCAN M., GÜRMAN G., BEKSAÇ M., et al.
Ankara Üniversitesi Tıp Fakültesi Mecmuası, cilt.74, 2021 (Hakemli Dergi)

II. **Utility investigation of automated techniques in hematopoietic progenitor cell count and viability assessment in the Good Manufacturing Practice (GMP) setting**
Kılıç P., Bay M., Baydın P., Şeker Ş., Coşkun Ö., Ülker O. L., Parmaksız M., Bitirim C. V., Cevheroğlu O., Deniz G. C., et al.
Experimental Biomedical Research, cilt.3, sa.4, ss.231-238, 2020 (Hakemli Dergi)

III. **Investigating the Presence of Chronic Myeloid Leukemia Leukemic Stem Cells (CML LSCs) in Patients with Tyrosine Kinase Inhibitors Who Achieved Cytogenetic / Molecular Response**
NARLI ÖZDEMİR Z., USLU A., TOPRAK S. K., TOPÇUOĞLU P., DALVA K., İLHAN O.
Hematological Disease and Therapies, 2018 (Hakemli Dergi)

IV. **HLA tissue status in patients with gluten sensitive enteropathy Gluten enteropatili hastalarda HLA gruplari**
Tezel A., Ulker A., ENSARİ A., Baysal C., DALVA K., Dagli U., Serin A., Over H., Alkim C.
Turkish Journal of Gastroenterology, cilt.9, sa.3, ss.269-271, 1998 (Scopus)

Kitap & Kitap Bölümleri

I. **Renal transplantasyon için HLA uyumunun değerlendirilmesi.**
DALVA K.
Türkiye Klinikleri Üroloji - Özel Konular Renal Transplantasyon: Temel Konular, Cerrahi Süreç ve Transplant Takibi, Akbay Erdem, Editör, Türkiye Klinikleri, Ankara, ss.1-10, 2023

II. **HLA ve Allojenik Nakil Özelinde HLA Sistemi**
DALVA K.
HematoLog,, Hematopoietik Kök Hücre Nakli, Hayri Özsan, Muhit Özcan, Editör, Galenos, Ankara, ss.92-102, 2019

III. **Akan Hücre Ölçer(Flow Cytometry) Genel prensipler**
DALVA K.
Hematolog, Hematologlar için İmmunoloji, Tevfik Akoğlu, Cem Ar, Türkan Patıroğlu, Editör, Galenos, Ankara, ss.185-190, 2016

IV. **HLA typing with sequence-specific oligonucleotide primed PCR (PCR-SSO) and use of the Luminex™ technology.**
DALVA K., BEKSAÇ M.

Bone Marrow and Stem Cell Transplantation,Methods in Molecular Biology, Meral Beksaç, Editör, HUMANA PRESS INC, 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA, Totowa, ss.87-99, 2014

Hakemli Kongre / Sempozyum Bildiri Kitaplarında Yer Alan Yayınlar

I. **Mononuclear Cell Distribution Analysis in Peripheral Blood as regards Individual Discrepancies**
Kılıç P., Ipek Ş., Coşar B., Yalçın M., Savran B. N., Korkmaz F. N., Dalva K., Şahin M., Gürman G.
Uluslararası Sağlık Araştırmaları Kongresi 2022, Ankara, Türkiye, 8 - 09 Aralık 2022

II. **Novel targets detected by next generation sequencing among triple refractory patients can be clinically targetable**
CENGİZ SEVAL G., KUZU I., Yüksel S., YILMAZ H., Yavuz G., KAYGUSUZ G., DALVA K., ÖZCAN M., BEKSAÇ M.
19th International Myeloma Society Annual Meeting, 25 Ağustos 2022

III. **Ex Vivo Epigenetic Modification with Valproic Acid (VPA) Plus Nicotinamide (NAM) Results in Expansion of Umbilical Cord Blood Hematopoietic Progenitors Leading to Faster Engraftment and Chimerism in In Vivo Mouse Xenograft Model**
GEncer Öncül E. B., Turasan E., Akın H. Y., YURDAKUL MESUTOĞLU P., SEVAL M. M., ÇAĞAN M., KOÇ F. A., BEKSAÇ M. S., DALVA K., BEKSAÇ M.
2022 Tandem Meetings of ASTCTTM and CIBMTR, Amerika Birleşik Devletleri, 23 Nisan 2022

IV. **Ankara Üniversitesi Tıp Fakültesi Doku Tiplendirme Laboratuvarına Anti-HLA Antikorların Taranması ve Antijene Özgün Antikorların Belirlenmesi İçin İletilen Örneklerden Elde Edilen Verilerin Bir Analizi**
Dalva K., Öz M. D., Özartam S., Yılmaz F., Bağlan Ö., Aksoy R., Kumru M., Şengül Ş., İlhan O.
8.Ulusal Transplantasyon İmmunolojisi ve Genetiği Kongresi, Antalya, Türkiye, 14 - 17 Nisan 2022, ss.1-85

V. **Organ Nakil Merkezinde Takip Edilen ve Yapılan Çapraz Karşılaştırma Test Sonuçları Pozitif Bulunduğu Için Bekleme Listesine Alınan Olguların Bir Değerlendirmesi**
Aksoy R., Kumru G., Aktar M., Şengül Ş., Keven K., Dalva K.
8. Ulusal Transplantasyon İmmünolojisi ve Genetiği Kongresi, Antalya, Türkiye, 14 - 17 Nisan 2022, ss.27-29

VI. **QUANTIFICATION OF MRD AT 10-5 BY FLOW IN THE STEM CELL GRAFT CORRELATES WITH MARROW MRD AND PFS FOLLOWING AHCT AMONG PATIENTS DIAGNOSED WITH MM**
CENGİZ SEVAL G., DALVA K., ÖZ M. D., GÜRMAN G., İLHAN O., BEKSAÇ M.
48th Annual Meeting of the EBMT, 19 Mart 2022

VII. **Amniyon Sıvısının, VPA İle Ekspande Hematopoietik Kök Hücre Nakli Sonrası Engrafmana Etkisinin İn Vivo Araştırılması**
ÖNCÜL E. B. G., TURASAN E., YOUSEFZADEH M., AKIN H. Y., YURDAKUL MESUTOĞLU P., DALVA K., BEKSAÇ M.
14. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Amerika Birleşik Devletleri, 10 Mart 2022

VIII. **İKİNCİ ALLOJENEİK KÖK HÜCRE NAKLİ: GERÇEK YAŞAM VERİSİ**
KIRCALI E., CENGİZ SEVAL G., ÖZTÜRK C., YILMAZ H., Yavuz G., Karakaya B., DALVA K., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., et al.
14. Ulusal kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, 10 Mart 2022

IX. **Post-Induction Undetectable Minimal Residual Disease at 10-5 Sensitivity Level within Marrow and/or Stem Cell Graft Overrides Cytogenetic High Risk**
CENGİZ SEVAL G., DALVA K., ÖZ D., BAKANAY S., SOYDAN E., GÜRMAN G., İLHAN O., BEKSAÇ M.
63rd ASH Annual Meeting and Exposition, Amerika Birleşik Devletleri, 11 Aralık 2021

X. **Postinduction minimal residual disease (MRD) within stem cell graft (gMRD) correlates with marrow MRD (mMRD) and progression free survival (PFS) following autologous stem cell transplantation**
CENGİZ SEVAL G., DALVA K., ÖZ M. D., ÖZTÜRK S., SOYDAN E., GÜRMAN G., İLHAN O., BEKSAÇ M.
18th International Myeloma Workshop, Amerika Birleşik Devletleri, 8 - 11 Eylül 2021

XI. **Haplotypes rich in activating killer-cell immnuglobulin-like receptor genes are associated with delay on age of myeloma onset**
AKIN H., CENGİZ SEVAL G., ATİLLA P., YURDAKUL MESUTOĞLU P., TANER O., ALNIAÇIK R., DALVA K., GÜRMAN G.,

BEKSAÇ M.
18th International Myeloma Workshop, Amerika Birleşik Devletleri, 8 - 11 Eylül 2021

XII. **A prospective analysis on the frequency and predictive value of minimal residual disease assessment by flow cytometry and PET-CT imaging among myeloma patients on/off maintenance**
BEKSAÇ M., CENGİZ SEVAL G., ŞAHİN U., MERTER M., İPEK Ş., ÖZKAN E., DALVA K.
23rd Congress of the European Hematology Association, 2021, 14 Haziran 2018, ss.249

XIII. **PHENOTYPES OF BONE MARROW MONOCYTES IN STEM CELL TRANSPLANTATION FOR ACUTE LEUKEMIA: A DESCRIPTIVE PILOT STUDY**
Yüksel M., Kırcalı E., Öztürk C., Yilmaz H., Koyun D., İpek Ş., Cengiz Seval G., Civriz Bozdağ S., Toprak S. K., Topçuoğlu P., et al.
8th International Congress on Leukemia Lymphoma Myeloma, İstanbul, Türkiye, 21 - 22 Mayıs 2021, sa.63, ss.48

XIV. **Killer Immunoglobulin-like Haplotype BB is Observed More Frequently Among Myeloma Cases Compared to Healthy Controls**
AKIN H. Y., ATACA ATİLLA P., YURDAKUL MESUTOĞLU P., CENGİZ SEVAL G., OTLU T., ALNIAÇIK R., DALVA K., GÜRMAN G., BEKSAÇ M.
8th International Congress Leukemia Lymphoma Myeloma (ICLLM), 21 - 22 Mayıs 2021

XV. **Yurt İçi Ve Yurt Dışı Gönüllü Akaraba Dışı Vericilerde HLA Özdeşlik Durumu : 10/10 >9/10 Mu Yoksa En Büyük HLADPB1 Mi?**
YÜKSEL M., CENGİZ SEVAL G., DALVA K., CEYLAN G., AKAL F., CİVRİZ BOZDAĞ S., TOPRAK S. K., TOPÇUOĞLU P., GÜRMAN G., BEKSAÇ M.
13. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, 2 - 03 Nisan 2021

XVI. **In Vitro Semisolid Agar Veya Sıvı Kültür Koşullarında Vpa Ve Nam Gibi Küçük Moleküller Aracılığı İle Hematopoietik Kök Hücre Ekspansiyonu Kinetikleri**
DALVA K., AKIN H. Y., ÖNCÜL E. B. G., TURASAN E., YOUSEFZADEH M., ŞEKER E., SÜT H., ÇAĞAN M., YURDAKUL MESUTOĞLU P., BEKSAÇ M.
13. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, 2 - 03 Nisan 2021

XVII. **KÖK HÜCRE ÜRÜNÜNDEKİ CD34 HÜCRE ALT GRUPLARI VE ENGRAFMAN İLE İLİŞKİSİ**
CENGİZ SEVAL G., TOPÇUOĞLU P., DALVA K., İLHAN O., YÜKSEL M., CİVRİZ BOZDAĞ S., TOPRAK S. K.
46. Ulusal Hematoloji Kongresi, Türkiye, 28 - 31 Ekim 2020

XVIII. **MM HASTALARINDA TANI SIRASINDA, TEDAVİ SONRASINDA IL-10, VEGF DÜZEYLERİ VE KEMİK İLİĞİNDEKİ PARAMETRELERLE İLİŞKİSİ**
CENGİZ SEVAL G., DALVA K., TOPRAK S. K., MEMİŞ F.
42. Ulusal Hematoloji Kongresi, Türkiye, 28 - 31 Ekim 2020

XIX. **AKUT MYELOBLASTİK LÖSEMİ HASTALARINDA NÜKLEOFOSMİN MUTASYONU MİNİMAL REZİDÜEL HASTALIK TAKİBİNDE YOL GÖSTERİCİMİDİR**
CENGİZ SEVAL G., ÖZCAN M., TOPÇUOĞLU P., DEMİRER T., BEKSAÇ M., CİVRİZ BOZDAĞ S., TOPRAK S. K., ARSLAN Ö., DALVA K., GÜRMAN G., et al.
42.Ulusal Hematoloji Kongresi, Türkiye, 28 - 30 Ekim 2020

XX. **TİROZİN KİNAZ İNHİBİTÖRLERİNİ KESME KARARINDA KEMİKİLİĞİNDEKİ LÖSEMİK KÖK HÜCRE VARLIĞININ ÖNEMİ**
İLHAN O., NARLI ÖZDEMİR Z., ARSLAN A., OKAY M., İPEK Ş., DALVA K., SAYDAM G., HAZNEDAROĞLU İ. C.
46. Ulusal Hematoloji Kongresi, Türkiye, 28 - 31 Ekim 2020

XXI. **CD34+ Cell Subsets in Stem Cell Products and Their Relationship with Engraftment Kinetics**
ERTEPE G., İPEK Ş., YILDIRIM Y., GÖZÜKARA M. G., DALVA K., CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., İLHAN O., et al.
46th Annual Meeting of the European Society for Blood and Marrow Transplantation, 29 Ağustos 2020

XXII. **DECISION TO STOP TYROSINE KINASE INHIBITORS (TKIS) WITH BONE MARROW LEUKEMIC STEM CELL LEVEL: DETECTION OF BCR-ABL IN PERIPHERAL BLOOD MAY NOT BE ENOUGH**
İLHAN O., NARLI ÖZDEMİR Z., ARSLAN A., OKAY M., İPEK Ş., DALVA K., SAYDAM G., HAZNEDAROĞLU İ. C.
25th European Hematology Congress Virtual, 11 - 21 Haziran 2020

XXIII. **Molecular Alterations Obtained by High-Throughput Methods in Multiple Myeloma Patients with**

Recurrent or Refractory to Heavy Treatment Regimens Could Guide Alternative Targeted Therapies
KUZU I., CENGİZ SEVAL G., YÜKSEL S., KAYGUSUZ G., DALVA K., ÖZCAN M., BEKSAÇ M.
2nd AMP Europe Congress on Clinical Genomics - Beyond the Somatic Mutation, Milan, İtalya, 11 Mayıs - 13 Şubat 2020, cilt.22, ss.35

XXIV. **Molecular Alterations Obtained by High-Throughput Methods in Multiple Myeloma Patients with Recurrent or Refractory to Heavy Treatment Regimens Could Guide Alternative Targeted Therapies**
KUZU I., CENGİZ SEVAL G., YÜKSEL M., KAYGUSUZ G., DALVA K., ÖZCAN M., BEKSAÇ M.
2nd AMP Europe Congress on Clinical Genomics - Beyond the Somatic Mutation, 11 - 13 Mayıs 2020

XXV. **AKRABA DIŞI VERİCİDEN KHN SÜRECİ BİLEŞENLERİNİN NAKİL ZAMANLAMASINA ETKİSİ: NAKİL ZAMANI DAHA ERKENE ÇEKİLEBİLİR Mİ?**
CENGİZ SEVAL G., TOPÇUOĞLU P., BEKSAÇ M., YÜKSEL M., GÜRMAN G., DALVA K., TOPRAK S. K., CİVRİZ BOZDAĞ S.
12.Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Türkiye, 5 - 07 Mart 2020

XXVI. **CD34 VE İMMUNEFEKTÖR HÜCRE SAYIMININ TRANSPLANTASYON SONUÇLARINA ETKİSİ**
CENGİZ SEVAL G., ÖZCAN M., TOPÇUOĞLU P., DEMİRER T., BEKSAÇ M., CİVRİZ BOZDAĞ S., TOPRAK S. K., ARSLAN Ö., USLU A., DALVA K., et al.
12. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Türkiye, 5 - 07 Mart 2020

XXVII. **Hematolojik malignitelerde nakil sonrası hematogon değerlerinin prognoza etkisi var mıdır?**
CENGİZ SEVAL G., DALVA K., TOPRAK S. K.
12.Ulusal Kemik iliği transplantasyonu ve hücresel tedaviler kongresi, Türkiye, 5 - 07 Mart 2020

XXVIII. **CD34+ VE İMMUNEFEKTÖR HÜCRE SAYIMININ TRANSPLANTASYON SONUÇLARINA ETKİSİ**
Koyun D., Cengiz Seval G., Dalva K., Uslu A., Öztürk C., Kırcalı E., Civriz Bozdağ S., Toprak S. K., Topçuoğlu P., Arslan Ö., et al.
12. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Muğla, Türkiye, 5 - 07 Mart 2020, sa.159, ss.60-61

XXIX. **KIR Genotype and KIR Ligand Phenotypes That Improve the in Vitro Cord Blood or Autologous NK Cell Mediated Cytotoxicity Against Myeloma Marrow Plasma Cells**
Akin H. Y., Turasan E., Kircali E., AKKUŞ E., CENGİZ SEVAL G., Yurdakul-Mesutoglu P., DALVA K., BEKSAÇ M.
Transplantation and Cellular Therapy (TCT) Meetings of ASTCT and CIBMTR, Florida, Amerika Birleşik Devletleri, 19 - 23 Şubat 2020, cilt.26

XXX. **Kronik Myeloid Lösemi (KML) Hastalarında KML Kök Hücresi BCR-ABL' den Bağımsız Prognostik Bir Faktör Olabilir mi?**
İLHAN O., NARLI ÖZDEMİR Z., ARSLAN A., OKAY M., İPEK Ş., DALVA K., SAYDAM G., HAZNEDAROĞLU İ. C.
45. Ulusal Hematoloji Kongresi, Türkiye, 30 Ekim - 02 Kasım 2019

XXXI. **Large Granular Lymphocytosis and Its Impact on Long Term Clinical Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation: 14-Year Follow-up Data**
CENGİZ SEVAL G., Uslu A., Kircali E., CİVRİZ BOZDAĞ S., DALVA K., TOPRAK S. K., Yuksel M. K., TOPÇUOĞLU P., KUZU I., ARSLAN Ö., et al.
61st Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Florida, Amerika Birleşik Devletleri, 7 - 10 Aralık 2019, cilt.134

XXXII. **Next Generation Sequencing May be Helpful in Designing Novel Combinations Among Heavily Pretreated Myeloma Patients, Refractory to All Available Approved Anti-Myeloma Drugs**
CENGİZ SEVAL G., KUZU I., YÜKSEL S., KAYGUSUZ G., DALVA K., ÖZCAN M., BEKSAÇ M.
61st Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Florida, Amerika Birleşik Devletleri, 7 - 10 Aralık 2019, cilt.134

XXXIII. **GENC BİR HASTADA SPLENİK DİFFUZ KIRMIZI PULPA LENFOMA OLGUSU**
Kırcalı E., ÖKSÜZ N. E., KUTLAY N., DALVA K., KUZU I., YÜKSEL M.
45 Ulusal Hematoloji Kongresi, Türkiye, 31 Ekim - 02 Kasım 2019

XXXIV. **NGS TUM SECENEKLERİ TUKETMİŞ NUKS VE DİRENCLİ MMHASTALARINDA ENDİKASYON DIŞI TEDAVİ OLUŞTURMADAREHBERLİK EDEBİLİR Mİ?**
CENGİZ SEVAL G., KUZU I., YÜKSEL S., DALVA K., ÖZCAN M., BEKSAÇ M.
45. Ulusal Hematoloji Kongresi, Türkiye, 31 Ekim - 02 Kasım 2019

XXXV. **Clonal plasma cell detection by high sensitive flow cytometry in aphaeresis product is poor prognostic and not increased by use of plerixafor alone**
CENGİZ SEVAL G., Uslu A., DALVA K., Bakanay S. M., Merter M., Sahin U., İLHAN O., BEKSAÇ M.
45th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT), Frankfurt, Almanya, 24 - 27 Mart 2019, cilt.54, ss.496-497

XXXVI. **Plerixafor, Periferik Kök Hücre Ürününde Akım Sitometri İle Saptanabilen Klonal Plazma Hücre Kontaminasyonunu Etkiler mi?**
CENGİZ SEVAL G., USLU A., DALVA K., BAKANAY ÖZTÜRK Ş. M., MERTER M., ŞAHİN U., İLHAN O., BEKSAÇ M.
11. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Türkiye, 1 - 03 Mart 2019

XXXVII. **Riedel Tiroiditli Hastalarin Klinik, Laboratuar, Patolojik ve Immunolojik Ozelliklerinin Belirlenmesi: Cok merkezli prospektif calisma**
GÖKÇAY CANPOLAT A., CİNEL M., TAŞKALDIRAN I., KORKMAZ H., DEMİR Ö., ERSOY R., BERKER D., DAĞDELEN S., DALVA K., SAK S., et al.
8. Türkiye Tiroid Hastalıkları Kongresi, Türkiye, 14 - 15 Aralık 2018

XXXVIII. **Comparision of Outcomes According to HLA Disparity in Acute Leukemia Patients: A Single Cente Institution Experience**
TOPÇUOĞLU P., CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., DALVA K., ARSLAN Ö., ÖZCAN M., DEMİRER T., İLHAN O., et al.
60th ASH Annual Meeting and Exposition, 01 Aralık 2018

XXXIX. **Kır2ds4'ün Miyelom Plazma Hücrelerine Karşı Otolog Veya Kordon Kanı Doğal Öldürücü Hücre Aracılıklı Toksisitede Rolü**
YURDAKUL MESUTOĞLU P., AKIN H., BUNSUZ M., TURASAN E., MERTER M., ÖZTÜRK C., DALVA K., BEKSAÇ M.
44. Ulusal Hematoloji Kongresi, Türkiye, 31 Ekim - 03 Kasım 2018

XL. **KIR 2DS4 May Influence Autologous and Cord Blood(CB) Natural Killer (NK)Cell Mediated in Vitro Cytotoxicity Against Freshly Isolated Human Bone Marrow Myeloma Plasma Cells and Cell Lines**
Mesutoglu P. Y., Akin H. Y., Bunsuz M., Turasan E., Merter M., Ozturk C., DALVA K., BEKSAÇ M.
60th Annual Meeting of the American-Society-of-Hematology (ASH), California, Amerika Birleşik Devletleri, 1 - 04 Aralık 2018, cilt.132

XLI. **Residual Clonal Plasma Cells Detected By Flow Cytometry at 10(-4)level within Autologous Stem Cell Grafts Is Associated with Significantly Less Overall Survival**
CENGİZ SEVAL G., DALVA K., BAKANAY ÖZTÜRK Ş. M., Merter M., Sahin U., Uslu A., Ozturk C., İLHAN O., BEKSAÇ M.
60th Annual Meeting of the American-Society-of-Hematology (ASH), California, Amerika Birleşik Devletleri, 1 - 04 Aralık 2018, cilt.132

XLII. **Akut Miyeloid Lösemide Nakil Öncesi ve Nakil Sonrası +28. Gün Değerlendirilen Minimal Kalıntı Hastalığın Hastalık Seyrine Etkisi**
DALVA K., NARLI ÖZDEMİR Z., ŞAHİN U., USLU A., MURADOVA B., CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., TOPRAK S. K., TOPÇUOĞLU P., ARSLAN Ö., et al.
44. Ulusal Hematoloji Kongresi, Antalya, Türkiye, 31 Ekim - 03 Kasım 2018, ss.245-246

XLIII. **KIR2DS4'ÜN MİYELOM PLAZMA HÜCRELERİNE KARŞIOTOLOG VEYA KORDON KANI DOĞAL ÖLDÜRÜCÜ HÜCREARACILIKLI TOKSİSİTEDE ROLÜ**
YURDAKUL MESUTOĞLU P., Akın H. Y., Bunsuz Şengün M., Turasan E., MERTER M., Öztürk C., DALVA K., BEKSAÇ M.
44. Ulusal Hematoloji Kongresi, Antalya, Türkiye, 31 Ekim - 03 Kasım 2018

XLIV. **Hematopoietik kök hücre nakli için toplanan kemik iliği materyallerinde sayılan cd34 pozitif hücreler: Cd34 pozitif gen hematogonlara dikkat**
DALVA K., Öz m. d., hakkoloğlu ş., avcu f., ERTEM M., İLHAN O., GÜRMAN G.
44. ulusal hematoloji kongresi, Türkiye, 31 Ekim - 03 Kasım 2018

XLV. **İndüksiyon Mu Hazırlama Rejimi Mi Daha Önemli? İndüksiyon Sonrası Kalıntı Hastalığın Saptanamaması Bir Prognostik Gösterge Olabilir**
CENGİZ SEVAL G., BAKANAY ÖZTÜRK Ş. M., MERTER M., ŞAHİN U., USLU A., NARLI ÖZDEMİR Z., öztürk c., DALVA K., İLHAN O., BEKSAÇ M.
44. Ulusal Hematoloji Kongresi, Antalya, Türkiye, 31 Ekim - 03 Kasım 2018

XLVI. **AKUT LÖSEMİ HASTALARINDA HLA UYUŞUMSUZLUĞUNUNNAKİL SONUÇLARINA ETKİSİ: TEK MERKEZ DENEYİMİ**
CENGİZ SEVAL G., NARLI ÖZDEMİR Z., TATAR L., SÖKMEN M., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., DALVA K., ARSLAN Ö., ÖZCAN M., et al.
44. Ulusal Hematoloji Kongresi, Türkiye, 31 Ekim - 03 Kasım 2018

XLVII. **A prospective analysis on the frequency and predictive value of minimal residual disease asessment by flow cytometry and PET-CT imaging among myeloma patients on/off maintenance**
BEKSAÇ M., CENGİZ SEVAL G., ŞAHİN U., MERTER M., İPEK Ş., ÖZKAN E., DALVA K.
23rd Congress of European Hematology Association, 14 - 17 Haziran 2018

XLVIII. **Impact Of Mesenchymal Stromal Cells On In Vıtro Growth Of Fresh Human Myeloma Plasma Cells And On Autologous/Cord Blood Nk Cell Medıated Cytotoxıcıty**
YURDAKUL MESUTOĞLU P., AKIN H., AYDIN G., SENGUN M., TURASAN E., DALVA K., BEKSAÇ M.
ISCT 2018 Annual Meeting, 2 - 05 Mayıs 2018

XLIX. **A Preliminary Analysis of Inherited Immune Checkpoint Control in Multiple Myeloma: Relative Frequency of Inhibitory or Activating Type Killer Immunoglobulin like Receptors and Their Cognate Ligands HLA-C1 and -C2**
BEKSAÇ M., YURDAKUL P., AKIN H., AYDIN G., ŞENGÜN M., ŞAHİN U., MERTER M., DALVA K.
59th American Society of Hematology Annual Meeting, 9 - 12 Aralık 2017

L. **Multipl miyelomda Killer Immunoglobulin like Reseptörleri (KIR) ve ligandları ile HLA- Grup C1 ve C2'nin sıklığı**
BEKSAÇ M., YURDAKUL P., AKIN H. Y., AYDIN G., ŞENGÜN M. B., ŞAHİN U., MERTER M., DALVA K.
43. Ulusal Hematoloji Kongresi, Antalya, Türkiye, 1 - 04 Kasım 2017

LI. **Increased expression of CD24 in Glioblastoma Cell Lines after treatment with Temozolomide and Bortezomib**
AKÇORA YILDIZ D., ÖZKAN T., DALVA K., UĞUR H. Ç., SUNGUROĞLU A., Özkanca Ş.
9th Annual Conference onStem Cell and Regenerative Medicine, Berlin, Almanya, 25 - 26 Eylül 2017

LII. **HLA C1/C1 homozygosity decreases relapse rate after allogeneic hematopoietic stem cell transplantation (Allo-HSCT) in acute myeloid leukemia (AML) patients**
Atilla E., Dalva K., Atilla P. A., TOPRAK S. K., Topcuoglu P., Gulbas Z., Arat M., Yesilipek A., Savran F. O., Beksac M.
43rd Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT), Marseille, Fransa, 26 - 29 Mart 2017, cilt.52

LIII. **Isolation And Culture Of Good Manufacturing Practice Grade Human Bone Marrow Derived Mesenchymal Stem Cells For Clinical Applications**
ELÇİN A. E., Şeker Ş., BAYDIN P., DALVA K., PARMAKSIZ M., LALEGÜL Ö., ÇUBUKÇUOĞLU DENİZ G., ELHAN A. H., GÜRMAN G., ARSLAN Ö., et al.
22nd International Symposium on Biomedical Science & Engineering BIOMED, Ankara, Türkiye, 12 Mayıs 2017

LIV. **EX VIVO EXPANSION OF HUMAN UMBILICAL CORD BLOOD HEMATOPOIETIC STEM CELLS (HSCS) WITH VALPROIC ACID (VPA) OR NEUROTROPHIC FACTOR (NTF)**
Akin H., YURDAKUL P., Aydin G., DALVA K., BEKSAÇ M.
ISCT 2018 MONTREAL ANNUAL MEETING, 2 - 05 Mayıs 2017, cilt.19, ss.83

LV. **Notch Ligandı Fibronektin Valproik Asit Nikotinamid ile Kordon Kanı Kök Hücrelerinin Ex Vivo Ekspansiyonu**
Yurdakul P., Gencer E. B., Akin H. Y., DALVA K., KATLAN D. C., BEKSAÇ M. S., BEKSAÇ M.
42. Ulusal Hematoloji Kongresi, Türkiye, 19 - 22 Eylül 2016

LVI. **CD34 POSITIVE CELL COUNT DETECTED BY MULTI-COLOR FLOW CYTOMETRY (MFC) AFTER FIRST INDUCTION THERAPY IN ACUTE MYELOID LEUKEMIA (AML) EFFECTS ON SURVIVAL AND RELAPSE**
Atilla E., Atilla P. A., CİVRİZ BOZDAĞ S., YÜKSEL M., Topcuoglu P., Arslan O., Beksac M., Ozcan M., Ilhan O., Akan H., et al.
21st Congress of the European-Hematology-Association, Copenhagen, Danimarka, 9 - 12 Haziran 2016, cilt.101, ss.682

LVII. **IS IT POSSIBLE TO DIAGNOSE LOW RISK MYELODYSPLASTIC SYNDROME (MDS) BY FLOW CYTOMETRY?**
Atilla E., Atilla P. A., Turedi O., CİVRİZ BOZDAĞ S., TOPRAK S. K., Akan H., Beksac M., Arslan O., Topcuoglu P., Ozcan M., et al.
21st Congress of the European-Hematology-Association, Copenhagen, Danimarka, 9 - 12 Haziran 2016, cilt.101, ss.506

LVIII. **Comparative Proteomic Analysis of Bone Marrow Plasma Cells By Using Mass Spectrometry Based Bottom up Proteomic Strategies**
Beycan A., Demiralp D. F. O., DALVA K., BEKSAÇ M.
57th Annual Meeting of the American-Society-of-Hematology, Florida, Amerika Birleşik Devletleri, 5 - 08 Aralık 2015, cilt.126

LIX. **Expression and in Vitro Binding of Protease Activated Receptor1 (PAR1) with Novel Anti-PAR1 Molecules: Data on Fresh Myeloma Marrow Plasma Cells and Human Myeloma Cell Lines**
BEKSAÇ M., Ataca P., Atesagaoglu B., DALVA K., Hidayat A. N., Yalcin I., Aki E. Y., ÖZKAN T., Papanikalaou X., Usmani S. Z., et al.
57th Annual Meeting of the American-Society-of-Hematology, Florida, Amerika Birleşik Devletleri, 5 - 08 Aralık 2015, cilt.126

LX. **Anti Miyelom için Yeni Bir Hedef Proteaz Aktive Reseptör 1 PAR1 in Myelom Plazma Hücrelerinde ve İnsan Myelom Hücre Dizilerinde İfadesi ve PAR1 Bağlayan Yeni Moleküllerin in vitro Etkileri**
ATACA P., ERTAN BOLELLİ T., ÖZKAN T., DALVA K., AKI YALÇIN E. E., YALÇIN İ., BEKSAÇ M.
41. Ulusal Hematoloji Kongresi, Türkiye, 21 - 24 Ekim 2015

LXI. **Follow up of del 5 q MDS patients with or without other chromosomal abnormalities**
TÜREDİ Ö., ATACA P., TUNCALI T., ATİLLA E., VİCDAN N. A., DURMAZ C. D., DALVA K., KUTLAY N., KARABULUT H. G., ILGIN RUHİ H., et al.
10th European Cytogenetics Conference, 4 - 07 Temmuz 2015, ss.102

LXII. **CML leukemic stem cell CML LCS Its existence in patients who achieved cytogenetic molecular response under treatment of TKI**
İLHAN O., USLU A., TOPRAK S. K., TOPÇUOĞLU P., ATİLLA E., ATACA P., ÖZTÜRK A., DALVA K., ARSLAN Ö., ÖZCAN M.
ASCO 2015, 29 - 02 Mayıs 2015

LXIII. **CML leukemic stem cell (CML LSC): Its existence in patients who achieved cytogenetic/molecular response under treatment of TKI.**
Ilhan O., Uslu A., TOPRAK S. K., Topcuoglu P., Atilla E., Ataca P., Ozturk A., Dalva K., Arslan O., Ozcan M.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, Amerika Birleşik Devletleri, 29 Mayıs - 02 Haziran 2015, cilt.33

LXIV. **HLA TYPING OF A MULTITRANSFUSED SCID PATIENT: WHAT NGS CAN TELL US?**
DALVA K., van de Pasch L., Topdagi D., Karagozlu S., Adema J., Aydincak H., Sertel S., Uguz E., Atilgan N., Rozemuller E., et al.
European-Federation-for-Immunogenetics Conference, Geneva, İsviçre, 26 - 29 Nisan 2015, cilt.85, ss.380

LXV. **allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria Single Centre Experienc**
ŞAHİN U., MERTER M., ATİLLA E., TOPÇUOĞLU P., TOPRAK S. K., İLHAN O., YÜKSEL M., ÖZCAN M., CİVRİZ BOZDAĞ S., DALVA K.
BONE MARROW TRANSPLANTATION, 22 - 25 Mart 2015

LXVI. **ALOGENEİC STEM CELL TRANSPLANTATION IN ADULT PATIENTS WITHPAROXYSMAL NOCTURNAL HEMOGLOBINURIA SINGLE CENTER EXPERIENCE**
MERTER M., ŞAHİN U., ATİLLA E., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., DALVA K., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M.
41.EBMT MEETING, 24 - 26 Mart 2015

LXVII. **Are there any optimal cell doses for graft repopulation in the Bone Marrow-Derived Allogeneic Hematopoietic Stem Cell Transplantations?**

Ataca P., Atilla E., Altas U., Bay M., Dalva K., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., Topcuoglu P., Arslan O., et al.
41st Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation, İstanbul, Türkiye, 22 - 25 Mart 2015, cilt.50

LXVIII. **Identification of Genes in Wnt Signaling Pathway with DNA Microarray Analysis in Acute Myeloid Leukemia.**
Altınok Güneş B., Özkan T., Karadağ A., Özkeserli Z., Dalva K., Sayınalp N., Beksaç M., Yağcı A. M., Özdağ Sevgili H., Sunguroğlu A.
FEBS-EMBO, Paris, Fransa, 30 Ağustos - 04 Eylül 2014, ss.219

LXIX. **AKRABA DIŞI ALLOJENEİK HEMATOPOETİK HÜCRE NAKLİNDE HLA UYUŞUMUNUN ETKİSİ-TEK MERKEZ DENEYİMİ**
CENGİZ SEVAL G., TOPÇUOĞLU P., ÖZEN M., GÜNDÜZ M., ATİLLA E., DALVA K., ARSLAN Ö., ÖZCAN M., DEMİRER T., İLHAN O., et al.
8. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, 06 Mart 2014

LXX. **Chemosensitivity to Induction or High Dose Therapy, Pre/Post Transplant PET Negativity and Absence of Minimal Residual Disease within Mobilized Stem Cell Graft Predict Long Term Disease Free Survival in Multiple Myeloma**
Bakanay S. M., DALVA K., KÖKSOY E. B., Civit D., Ayyildiz E., ÖZCAN M., İLHAN O., BEKSAÇ M.
BMT Tandem Meetings, Texas, Amerika Birleşik Devletleri, 26 Şubat - 02 Mart 2014, cilt.20

LXXI. **Preliminary Results Of A Mass Spectrometry Based Bottom Up Proteomic Approach On Bone Marrow Plasma Cells From Patients With Multiple Myeloma (MM)**
Ayhan B., Demiralp D. O., Dalva K., Beksac M.
55th Annual Meeting of the American-Society-of-Hematology, Louisiana, Amerika Birleşik Devletleri, 7 - 10 Aralık 2013, cilt.122

LXXII. **Kiler Immunoglobulin Receptor(KIR) Ligands Are Associated with At Least Partial (HLA A*03, B*44) or Poorer (HLA B*51, C*04) Response to Thalidomide Among Patients with Multiple Myeloma Treated in Two Turkish Centers**
Suyani E., Bakanay S. M., DALVA K., Cakmak E., Haznedar R., Sncak G., BEKSAÇ M.
54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Georgia, Amerika Birleşik Devletleri, 8 - 11 Aralık 2012, cilt.120

LXXIII. **Minimal Residual Plasma Cell Content of Autulogous Grafts, Chemosensitivity to Induction or High Dose Therapy and Pre/Post Transplant PET Negativity Predict Long Term Disease Free Survival in Multiple Myeloma.**
Bakanay S. M., Dalva K., Koksoy B. E., Ayyildiz E., ÖZCAN M., İLHAN O., BEKSAÇ M.
54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Georgia, Amerika Birleşik Devletleri, 8 - 11 Aralık 2012, cilt.120

LXXIV. **A case with therapy-related myelodysplastic syndrome secondary to acute myeloid leukemia**
Kaymak Cihan m., Yıldırım Ü. M., Paç A., Gül S., Duman R., Tekgündüz E., Terzi Y. K., KUTLAY N., DALVA K., Yurtçu A., et al.
VI. International Symposium on Myelodysplastic Syndrome and Bone Marrow Failures in Childhood, 23 - 26 Haziran 2012

LXXV. **The effect of cyclophosphamide with bortezomib as the mobilisation regimen on the graft quality and response of disease in multiple myeloma**
Topcuoglu P., Baslar S., CİVRİZ BOZDAĞ S., Dalva K., Ayyildiz E., Uysal A., GÜRMAN G., Ozcan M.
38th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation (EBMT), Geneva, İsviçre, 1 - 04 Nisan 2012, cilt.47

LXXVI. **AML'de CD34+ Hematopoetik Kök Hücrelerde Wnt Sinyal Yolağındaki Genlerin DNA Mikroarray Analizi ile Tanımlanması.**
Altınok Güneş B., Özkan T., Karadağ A., Özkeserli Z., Dalva K., Beksaç M., Sayınalp N., Yağcı A. M., Özdağ Sevgili H., Sunguroğlu A.
XII. Ulusal Tıbbi Biyoloji ve Genetik Kongresi , Antalya, Türkiye, 27 - 30 Ekim 2011, ss.51

LXXVII. **Peripheral stem cell apheresis in multiple myeloma in the era of new agents**
Bakanay S. M., Ayyildiz E., Arat M., Topcuoglu P., Soydan E., Dalva K., CİVRİZ BOZDAĞ S., Demir F., Demirer T., Arslan O., et al.
37th European Group for Bone and Marrow Transplantation/27th Meeting of the EBMT Nurses Group/10th Meeting of the EBMT Management Group, Paris, Fransa, 3 - 06 Nisan 2011, cilt.46

LXXVIII. **Effects of Atorvastatin Pretreatment on Endothelial Progenitors Cells After Coronary Surgery: A Randomized, Controlled Trial**
BARAN Ç., AKAR A. R., aslan ö., DURDU M. S., DALVA K., ZAİM Ç., Özyurda Ü.
STS 47TH ANNUAL MEETING, SAN DIEGO, Amerika Birleşik Devletleri, 31 Ocak - 02 Şubat 2011

LXXIX. **Comparison of the most frequent haplotypes of Turkish subjects in two registries: TRAN and DKMS**
BEKSAÇ M., Dalva K.
24th European Immunogenetics and Histocompatibility Conference/17th Annual Meeting of the Italian-Society-for-Immunogenetics-and-Transplantation-Biology, Florence, İtalya, 15 - 18 Mayıs 2010, cilt.75, ss.509

LXXX. **Significance of serial chimerism analysis in allogeneic haematopoietic cell transplantation for bone marrow failure: do stable mixed chimerism matter?**
Bakanay S. M., Arat M., Serbest E., Topcuoglu P., Soydan E. A., Bilgin A. U., CİVRİZ BOZDAĞ S., Dalva K., Guerman G.
36th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantat/9th Meeting of the EBMT Data-Management-Group/26th Meeting of the EBMT Nurses Group/2nd EBMT Qual Management Meeting, Vienna, Avusturya, 21 - 24 Mart 2010, cilt.45

LXXXI. **TRACKING OF DONOR TYPE GREN FLUORESCENT AND LUCIFERASE POSITIVE MARROW MONONUCLEAR OR MESENCHYMAL STEM CELLS IN POSTMORTEM SPINAL CORD HISTOPATHOLOGICAL SECTIONS FOR DETERMINATION OF REGENERATION IN A SPINAL CORD INJURY MODEL**
Beksac M., Kuzu I., Ozdemir M., Ayten M., Dalva K., Uckan D., Kilic E., Attar A., Beksac M., Kanpolat Y.
14th Annual Meeting of the European-Hematology-Association, Berlin, Almanya, 4 - 07 Haziran 2009, ss.66

LXXXII. **Results from satellite workshop on molecular chimerism quantification after allogenic stem cell transplantation**
Alizadeh M., Moine A., Constantinescu A. D., Balas A., Mazzi B., Porfirio B., Brown C., Dauber E., Bories D., Drouet M., et al.
23rd European Immunogenetics and Histocompatibility Conference, Ulm, Almanya, 9 - 12 Mayıs 2009, cilt.73, ss.395-396

LXXXIII. **HLA specificities/haplotypes of patients who have no matched donors available worldwide: a report from TRAN-Turkey**
DALVA K., Akal F., Basalp A., Uguz E., BEKSAÇ M.
23rd European Immunogenetics and Histocompatibility Conference, Ulm, Almanya, 9 - 12 Mayıs 2009, cilt.73, ss.451-452

LXXXIV. **Flow Cytometric Analysis of T Cell Functions in CML Patients Under Imatinib Therapy.**
Sahin D. G., DALVA K., Meric S., GÜRMAN G., ÖZCAN M., ARSLAN Ö., Arat M.
50th Annual Meeting of the American-Society-of-Hematology, San-Francisco, Kostarika, 6 - 09 Aralık 2008, cilt.112, ss.911

LXXXV. **FACTORS INVOLVED IN RESPONSE TO THALIDOMIDE IN MYELODYSPLASTIC SYNDROME: IMPACT OF HLA AND PROGNOSTIC FACTORS**
Bakanay S. M., Dalva K., Topcuoglu P., Bozdag-Civriz S., BEKSAÇ M., GÜRMAN G.
13th Congress of the European-Hematology-Association, Copenhagen, Danimarka, 12 - 15 Haziran 2008, cilt.93, ss.406-407

LXXXVI. **COMPARATIVE ANALYSIS OF MESENCHYMAL STEM CELL CONTENT DETECTED BY FLOW CYTOMETRY IN UMBILICAL CORD BLOOD, G-CSF MOBILIZED PERIPHERAL BLOOD, ADULT AND PEDIATRIC BONE MARROW OF HEALTHY DONORS**
Beksac M., Ersoy H. E., Dalva K., Uckan D. U., Meric S. M., Beksac M. S. B., Ertem M. E., Ilhan O. I., Beksac M. B.
13th Congress of the European-Hematology-Association, Copenhagen, Danimarka, 12 - 15 Haziran 2008, cilt.93, ss.524-525

LXXXVII. **HLA-A, -B, -C, -DR haplotypes, linkeage and frequencies observed in Ankara University, Turkey: a report from Tran**
BEKSAÇ M., Dalva K.
22nd European Immunogenetics and Histocompatibility Conference, Toulouse, Fransa, 2 - 05 Nisan 2008, cilt.71, ss.373

LXXXVIII. **Do the febrile neutropenic episodes during mobilisation have any effect on autologous stem cell collection yield in patients with myeloma and lymphoma?**
Topcuoglu P., Bilgin A. U., Ayyildiz E., Dalva K., Arslan O., Ilhan O., BEKSAÇ M., Arat M., Ozcan M.
34th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation/24nd Meeting of the EBMT-Nurses-Group/7th Meeting of the EBMT-Data-Management-Group, Florence, İtalya, 30 Mart - 02 Nisan 2008, cilt.41

LXXXIX. **The presence of thrombophilia and the development of thromboembolic complications in allogeneic haematopoietic cell transplantation**
Topcuoglu P., Gunaltay S., Dalva K., Bilgin A. U., Arat M., GÜRMAN G., Ozcan M.
34th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation/24nd Meeting of the EBMT-Nurses-Group/7th Meeting of the EBMT-Data-Management-Group, Florence, İtalya, 30 Mart - 02 Nisan 2008, cilt.41

XC. **The relation between the disparities of short tandem repeats between donor-recipient pair and the allogeneic haematopoietic cell transplantation outcome**
Serbest E., Topcuoglu P., Dalva K., Bilgin A. U., Soydan E., Ozcan M., Arslan O., Ilhan O., BEKSAÇ M., GÜRMAN G., et al.
34th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation/24nd Meeting of the EBMT-Nurses-Group/7th Meeting of the EBMT-Data-Management-Group, Florence, İtalya, 30 Mart - 02 Nisan 2008, cilt.41

XCI. **THE RELATION BETWEEN THE FREQUENCY OF PRESENCE OF THROMBOPHILIA AND THROMBOEMBOLIC COMPLICATIONS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (AHCT)**
Topcuoglu P., Gunaltay S., Dalva K., Bilgin A. U., Arat M., Ozcan M.
Annual Meeting of the American-Society-for-Blood-and-Marrow-Transplantation, California, Amerika Birleşik Devletleri, 13 - 17 Şubat 2008, cilt.14, ss.111

XCII. **THE IMPACT OF THE DISPARITIES OF SHORT TANDEM REPEATS (STR) BETWEEN DOONOR-RECIPIENT PAIR ON THE ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (AHCT) OUTCOME**
Serbest E., Topcuoglu P., Dalva K., Bilgin A. U., Soydan E. A., Ozcan M., Arslan O., Ilhan O., BEKSAÇ M., GÜRMAN G., et al.
Annual Meeting of the American-Society-for-Blood-and-Marrow-Transplantation, California, Amerika Birleşik Devletleri, 13 - 17 Şubat 2008, cilt.14, ss.111-112

XCIII. **The impact of disparity in short tandem repeats (STRS) analysis on the outcome of allogeneic hematopoietic cell transplantation (allo-HCT) from HLA-identical sibling donors**
Serbest E., Topcuoglu P., Dalva K., Soydan E. S., Arslan O. A., Ozcan M. O., Demirer T. D., Akan H. A., Konuk N., Uysal A. U., et al.
12th Congress of the European-Hematology-Association, Vienna, Avusturya, 7 - 10 Haziran 2007, cilt.92, ss.517

XCIV. **Dna hyperploidy is associated with both high plasma cell percentage & high beta 2 microglobulin and impairs survival in myeloma patientstreated with or without transplantation**
Dalva K., Soydan E. A., Kizil M., Topcuoglu R., Gungor F., ATASOY B. M., BEKSAÇ M.
12th Congress of the European-Hematology-Association, Vienna, Avusturya, 7 - 10 Haziran 2007, cilt.92, ss.402-403

XCV. **The determination of leukemic phenotype and minimal residual disease in acute myeloid leukemia by using flow cytometry**
Topcuoglu P., Dalva K., Meric S., Sahin S., Arat M., BEKSAÇ M.
12th Congress of the European-Hematology-Association, Vienna, Avusturya, 7 - 10 Haziran 2007, cilt.92, ss.19

XCVI. **Impact of HLA on availability of a donor, graft versus host disease frequency, and survival among 611 myeloma patients transplanted at three institutions from three continents**
BEKSAÇ M., Garcia Sanz R., Dalva K., Gungor F., Cevirgen T., Alcoceba M., Hungria V. T., Vayntrub T., Grumet F. C., Negrin R., et al.
11th International Myeloma Workshop/4th International Workshop on Wladenestroms Macroglobulinemia, Kos

Isl, Yunanistan, 25 - 30 Haziran 2007, cilt.92, ss.185

XCVII. **HemHLA (R) (Ankara, tr): a flexible software for HLA typing laboratories and registries that supports storage, transport and search functions on donor/recipient data**
Dalva K., Tuertekin M., Gueclue O., BEKSAÇ M.
21st European Immunogenetics and Histocompatibility Conference, Barcelona, İspanya, 5 - 08 Mayıs 2007, cilt.69, ss.529-530

XCVIII. **HLA-DR15 and HLA-DR3 are observed more frequently among allo-transplanted compared to auto-transplanted or non-transplanted patients, a finding observed in myeloma, but not CML, cases from various countries**
BEKSAÇ M., Dalva K., Stockerl-Goldstein K., Sanz R. G., Hungria V. T., Cevirgen T., Gungor F., Vayntrub T., Miguel J. S., Negrin R., et al.
21st European Immunogenetics and Histocompatibility Conference, Barcelona, İspanya, 5 - 08 Mayıs 2007, cilt.69, ss.514

XCIX. **Relationship between the mucositis seen after the allogeneic haematopoietic stem cell transplantation and the human leucocyte antigen types**
Kabacam G., Soydan E. A., Topcuoglu P., Dalva K., Ozdemir P., Ozcan M.
33rd Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation, Lyon, Fransa, 25 - 28 Mart 2007, cilt.39

C. **MULTİPL MİYELOMA VE MALİN LENFOMALI HASTALARDA OTOLOG PERİFERİK KÖK HÜCRE TOPLANMASINDA AFEREZ GÜN SAYISI ÖNGÖRÜLEBİLİR Mİ? - ANKARA HESAPLAMA FORMÜLÜ**
ARAT M., CENGİZ SEVAL G., SOYDAN E., AYYILDIZ E., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., GÜRMAN G., DALVA K., BEKSAÇ M., et al.
32. Ulusal Hematoloji Kongresi, 08 Kasım 2006

CI. **Two independent effects of immunoglobulin-like receptor (KIR) allele matching between siblings: Inhibitory KIR (iKIR) mismatches are associated with graft versus host disease (GVHD) while activatory KIR matches (aKIR) and cGVHD are associated with graft versus leukemia (GVL).**
Dalva K., Gungor F., Akcaglayan E. S., BEKSAÇ M.
48th Annual Meeting of the American-Society-of-Hematology, Florida, Amerika Birleşik Devletleri, 9 - 12 Aralık 2006, cilt.108

CII. **bcr,abl fusion binding HLA molecule frequencies among patients with CML**
Dalva K., Guven N., Sebest E., Cevirgen T., BEKSAÇ M., Ilhan O.
32nd Annual Meeting of the American-Society-for-Histocompatibility-and-Immunogenetics, California, Amerika Birleşik Devletleri, 16 - 20 Ekim 2006, cilt.67

CIII. **Class I and II antigens that are associated with rate or age at presentation of multiple myeloma: Preliminary results from two centers in Turkey**
Cevirgen T., Dalva K., Akcaglayan E. S., Arslan U., Ersoy F., BEKSAÇ M.
20th European Immunogenetics and Histocompatibility Conference, Oslo, Norveç, 8 - 11 Haziran 2006, cilt.67, ss.547-548

CIV. **Role of killer inhibitory receptor (KIR) allele and ligand mismatches (mm) in HLA identical sibling haematopoetic stem cell transplants**
Gungor E., Dalva K., Akcaglayan E. S., Oztuna D., BEKSAÇ M.
20th European Immunogenetics and Histocompatibility Conference, Oslo, Norveç, 8 - 11 Haziran 2006, ss.502

CV. **Follow-up of ADAMTS13 Enzyme and its relationship with clinical events after allogeneic haematopoietic stem cell transplantation**
CİVRİZ BOZDAĞ S., Gunaltay S., Dalva K., Ozcan M.
32nd Annual Meeting of the European-Group-for-Blood-and-Morrow-Transplantation/22nd Meeting of the EBMT-Nures-Group/5th Meeting of the EMBT-Data-Management-Group, Hamburg, Almanya, 19 - 22 Mart 2006, cilt.37

CVI. **HLA B51-DR04 phenotype which is an infrequent observation in multiple myeloma may be associated with longer disease-free survival: preliminary results from two centres in Turkey**
Dalva K., Cevirgen T., Soydan E., Ersoy F., BEKSAÇ M.
32nd Annual Meeting of the European-Group-for-Blood-and-Morrow-Transplantation/22nd Meeting of the EBMT-

Nures-Group/5th Meeting of the EMBT-Data-Management-Group, Hamburg, Almanya, 19 - 22 Mart 2006, cilt.37

CVII. **A new predictive and prognostic marker for de novo AML: Peripheral blood CD34 (pCD34) count at recovery following remission induction (RI) therapy (Supp. by Ankara university2003-0809114).**
Arat M., Topcuoglu P., YÜKSEL M., Dalva K., Gultekin G., GÜRMAN G., Arslan O., Ozcan M., BEKSAÇ M., Konuk N., et al.
47th Annual Meeting of the American-Society-of-Hematology, Georgia, Amerika Birleşik Devletleri, 10 - 13 Aralık 2005, cilt.106

CVIII. **Impact of harvest product volume in erythrocyte depletion of allogeneic or autologous bone marrow using COBE spectra**
SOYDAN e., AYYILDIZ E., DALVA K., TOPÇUOĞLU P., TOL M., ARSLAN Ö., İLHAN O., ARAT M.
15th Congress of the Interdisciplinary-European-Society-for-Haemapheresis-and-Haemotherapy, 5 - 09 Ekim 2005

CIX. **BCR,ABL fusion binding HLA molecule frequencies among patients with civil**
Dalva K., Serbest E., Gungor F., Akfirat H., BEKSAÇ M.
19th European Immunogenetics and Histocompatibility Conference, İstanbul, Türkiye, 23 - 26 Nisan 2005, cilt.6

CX. **Interleukin-10(IL-10)1082-A and tumor necrosis factor(TNF)alpha 238/308A genotypes are associated with earlier (younger than 55) onset of multiple myeloma**
BEKSAÇ M., Kizil M., Soydan E., Serbest E., Dalva K.
19th European Immunogenetics and Histocompatibility Conference, İstanbul, Türkiye, 23 - 26 Nisan 2005, cilt.6

CXI. **Evaluation of thrombophilia associated genetic mutations, coagulometric and immunological parameters in menopausal patients.**
Mollamahmutoglu S., Dalva K., Beksac S.
52nd Annual Meeting of the Society-for-Gynecologic-Investigation, Los-Angeles, Şili, 23 - 26 Mart 2005, cilt.12

CXII. **Both higher level of (bcr,abl) transcripts and high Hasford risk score are associated with cytogenetic response but absence of molecular remission during first line use of imatinib mesilate(IM): A finding not observed following use among interferon failures.**
TOPRAK S. K., Dalva K., Mizrak D., Arat M., Ozcan M., GÜRMAN G., Ilhan O., BEKSAÇ M.
46th Annual Meeting of the American-Society-of-Hematology, California, Amerika Birleşik Devletleri, 4 - 07 Aralık 2004, cilt.104

CXIII. **Interleukin-10(IL-10)1082-A and tumor necrosis factor(TNF)-Alpha 238/308A genotypes are associated with earlier (Younger than 55) onset of multiple myeloma.**
BEKSAÇ M., Kizil M., Soydan E., Serbest E., Dalva K.
46th Annual Meeting of the American-Society-of-Hematology, California, Amerika Birleşik Devletleri, 4 - 07 Aralık 2004, cilt.104

CXIV. **Allogeneic hemapoietic progenitor cell collection using four different cell separators: A retrospective comparative analysis.**
Arat M., Arslan O., Soydan E., Ayyildiz E., Dalva K., Tol M., Ozcan M., GÜRMAN G., Demirer T., Akan H., et al.
46th Annual Meeting of the American-Society-of-Hematology, California, Amerika Birleşik Devletleri, 4 - 07 Aralık 2004, cilt.104

CXV. **A comparison of the number of informative short tandem repeat (STR) loci between HLA identical donor-recipient pairs and the frequency of graft versus host disease (GVHD)**
Dalva K., Arat M., Serbest E., BEKSAÇ M.
18th European Histocompatibility Conference, Sofija, Bulgaristan, 8 - 11 Mayıs 2004, cilt.5

CXVI. **Apoptosis in the haematopoietic stem cell products obtained by continuous flow apheresis method in allogeneic peripheral stem cell transplantation**
Bakanay S., Arat M., Dalva K., Arslan O., BEKSAÇ M., Ayyildiz E., Ilhan O.
30th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation/20th Meeting of the EBMT-Nurses-Group/3rd Meeting of the EBMT-Data-Management-Group, Barcelona, İspanya, 28 - 31 Mart 2004, cilt.33

CXVII. **Occurrence of cytomegalovirus infection and/or viraemia shortens overall survival**
Topcuoglu P., Arat M., Soydan E., Dalva K., Ciftcioglu A., Akan H., Ilhan O., BEKSAÇ M.
30th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation/20th Meeting of the EBMT-Nurses-Group/3rd Meeting of the EBMT-Data-Management-Group, Barcelona, İspanya, 28 - 31 Mart 2004, cilt.33

CXVIII. **The impact of HLA-dr antigens on chronic graft-versus-host disease associated oral lichenoid lesions**

Sanli H., Ozdemir E., Arat M., Ekmekci P., Dalva K., BEKSAÇ M.
30th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation/20th Meeting of the EBMT-Nurses-Group/3rd Meeting of the EBMT-Data-Management-Group, Barcelona, İspanya, 28 - 31 Mart 2004, cilt.33

CXIX. **A comparison of the number of informative short tandem repeat loci between HLA identical donor-recipient pairs and the frequency of graft-versus-host disease**
Dalva K., Arat M., Serbest E., BEKSAÇ M.
30th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation/20th Meeting of the EBMT-Nurses-Group/3rd Meeting of the EBMT-Data-Management-Group, Barcelona, İspanya, 28 - 31 Mart 2004, cilt.33

CXX. **Fetal-obstetric parameters that decrease volume (V) or mononuclear cell content (MNC) do not influence total hematopoietic cell content (HSCC) in the cord blood (CB) harvest.**
Beksac M., Dalva K., Arat M., Beksac S.
45th Annual Meeting of the American-Society-of-Hematology, SAN DIEGO, CALIFORNIA, 6 - 09 Aralık 2003, cilt.102

CXXI. **Tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), interleukin-10 (IL-10), transforming growth factor-beta (TGF-beta) and interferon-gamma (INF-gamma) polymorphic single nucleotide allele frequencies in patients with multiple myeloma (MM): Disparities between the siblings and effect on treatment outcome.**
BEKSAÇ M., Kizil M., Soydan E., Serbest E., AKYERLİ BOYLU C., Ozcelik T., Dalva K.
45th Annual Meeting of the American-Society-of-Hematology, SAN DIEGO, CALIFORNIA, 6 - 09 Aralık 2003, cilt.102

CXXII. **In vitro binding and complement dependent cytotoxicity (CDC) of Rituximab(R) in patients with chronic B-lymphoproliferative disorders: Effects of glycosylphosphatidil inositol (GIP) expression and cyclosporin A (CsA).**
BEKSAÇ M., Dalva K., Akar G.
45th Annual Meeting of the American-Society-of-Hematology, SAN DIEGO, CALIFORNIA, 6 - 09 Aralık 2003, cilt.102

CXXIII. **Moleküler belirleyici saptanmış akut lösemili olgularda yanıtın polimeraz zincir reaksiyonu PCR ve floresan in situ hibridizasyon FISH ile izlenmesi**
YÜKSEL M., DALVA K., ARAT M., BEKSAÇ M.
XXX. Ulusal Hematoloji Kongresi, Türkiye, 10 - 12 Ekim 2003

CXXIV. **Reduction of stem cell content is a feasible approach in standard risk HLA identical sibling allogeneic peripheral or marrow transplants**
Arat M., Soydan E., Dalva K., Akan H., BEKSAÇ M.
29th Annual Meeting of the European Group for Blood and Marrow Transplantation/19th Meeting of the EBMT Nurses Group/2nd Meeting of the EBMT Data Management Group, İstanbul, Türkiye, 23 - 26 Mart 2003, cilt.31

CXXV. **The relation between T-helper subsets and the risk of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation**
Ozcan M., Topcuoglu P., BEKSAÇ M., Dalva K.
29th Annual Meeting of the European Group for Blood and Marrow Transplantation/19th Meeting of the EBMT Nurses Group/2nd Meeting of the EBMT Data Management Group, İstanbul, Türkiye, 23 - 26 Mart 2003, cilt.31

CXXVI. **Donor type epithelial cell repopulation in gastrointestinal mucosa following sex mismatch allogeneic peripheral blood transplantation: evidence for in vivo stem cell plasticity?**
Kuzu I., Idilman R., Arat M., Dalva K., Soykan I., Akan H., BEKSAÇ M.
29th Annual Meeting of the European Group for Blood and Marrow Transplantation/19th Meeting of the EBMT Nurses Group/2nd Meeting of the EBMT Data Management Group, İstanbul, Türkiye, 23 - 26 Mart 2003

CXXVII. **Kinetics of chimerism in sex-mismatched allogeneic hematopoietic cell transplantation with reduced-intensity conditioning**
GÜRMAN G., Arat M., Soydan E., Dalva K., TOPRAK S. K., YÜKSEL M., Meric S., BEKSAÇ M.
29th Annual Meeting of the European Group for Blood and Marrow Transplantation/19th Meeting of the EBMT Nurses Group/2nd Meeting of the EBMT Data Management Group, İstanbul, Türkiye, 23 - 26 Mart 2003, cilt.31

CXXVIII. **Comparative analysis of molecular response following interferon-alpha, imatinib mesilate or allogeneic stem cell transplantation (ASCT): best response is obtained with ASCT in chronic myeloid leukemia**
BEKSAÇ M., Arat M., Dalva K., Ilhan O., TOPRAK S. K., GÜRMAN G., Ozcan M., Arslan O., Konuk N., Uysal A.

29th Annual Meeting of the European Group for Blood and Marrow Transplantation/19th Meeting of the EBMT Nurses Group/2nd Meeting of the EBMT Data Management Group, İstanbul, Türkiye, 23 - 26 Mart 2003, cilt.31

CXXIX. **Long-term evaluation of hematopoietic and immune reconstitution following allogeneic peripheral blood hematopoietic cell transplantation during graft-versus-host disease**
Dilek I., GÜRMAN G., Dalva K., BEKSAÇ M., Ilhan O., Ozcan M., Akan H., Arslan O., Konuk N., Uysal A., et al.
29th Annual Meeting of the European Group for Blood and Marrow Transplantation/19th Meeting of the EBMT Nurses Group/2nd Meeting of the EBMT Data Management Group, İstanbul, Türkiye, 23 - 26 Mart 2003, cilt.31

CXXX. **Analysis of stem cell content and T-cell subsets in allogeneic peripheral stem cell harvest**
Arslan O., Arat M., Ayyildiz E., Dalva K., Kabacam G., Tol M., Ilhan O.
29th Annual Meeting of the European Group for Blood and Marrow Transplantation/19th Meeting of the EBMT Nurses Group/2nd Meeting of the EBMT Data Management Group, İstanbul, Türkiye, 23 - 26 Mart 2003, cilt.31

CXXXI. **Molecular response rates achieved in chronic myelogenous leukemia (CML) patients treated with interferon, imatinib mesylate (STI) or stem cell transplantation. A single institutional experience.**
BEKSAÇ M., Arat M., Dalva K., Ilhan O., GÜRMAN G., Ozcan M., Arslan O., Konuk N., Uysal A., Akan H.
44th Annual Meeting of the American-Society-of-Hematology, PHILADELPHIA, PENNSYLVANIA, 6 - 10 Aralık 2002, cilt.100

CXXXII. **Analysis of high and low risk chronic myeloid leukemia by gene expression profiling.**
AKYERLİ BOYLU C., BEKSAÇ M., Holko M., Frevel M., Dalva K., GÜRMAN G., Ilhan O., Ozcan M., Akan H., Williams B., et al.
44th Annual Meeting of the American-Society-of-Hematology, PHILADELPHIA, PENNSYLVANIA, 6 - 10 Aralık 2002, cilt.100

CXXXIII. **Preapheresis dendritic cell count predicts apheresis content in allogeneic PBSC collection.**
Ilhan O., Arslan O., Arat M., Dalva K., Ayyildiz E.
44th Annual Meeting of the American-Society-of-Hematology, PHILADELPHIA, PENNSYLVANIA, 6 - 10 Aralık 2002, cilt.100

CXXXIV. **Akut miyeloblastik lösemide indüksiyon sonrası toparlanma döneminde perifer CD34 düzeyinin prognostic önemi Bir pilot çalışma**
ARAT M., TOPÇUOĞLU P., DALVA K., YÜKSEL M., soydan e., AKAN H.
XXIX. Ulusal Hematoloji Kongresi, Türkiye, 25 - 27 Ekim 2002

CXXXV. **Telomeraz aktivitesinin malign plazma hücreleri ve eritroblastlar ile benign eritroblastlarda incelenmesi**
YÜKSEL M., DALVA K., AKYERLİ BOYLU C., BEKSAÇ M.
XXIX. Ulusal Hematoloji Kongresi, Türkiye, 25 - 27 Ekim 2002

Desteklenen Projeler

DALVA K., SUNGUROĞLU A., TÜBİTAK Projesi, Glioblastoma Multiforme GBM İlaç Direncinde Rol Oynayan CD133 Glioblastoma Kök Hücrelerini GKH Hedefleyen Terapötik Monoklonal Antikor Geliştirilmesi, 2014 - Devam Ediyor

Demirel S., Yanık Odabaş Ö., Dalva K., Doğanay B., Şermet F., Özmert E., TÜBİTAK Projesi, diyabetik makula ödemi patogenezinde inflamasyonun rolü:aköz flare yoğunluğu, aköz sitokin seviyeleri ve görüntüleme bulgularının karşılaştırılması, 2022 - 2024

Akbulut H., DALVA K., TÜBİTAK Projesi, Kanser Kök Hücre Hedefli gen tedavisi aracılı İmmunoterapi yöntemleri geliştirilmesi Proje no:119S451, 2019 - 2023

Esatoğlu A. E., Işgör Y. G., Dalva K., Doğan Ö., Kiliç M., AB Destekli Diğer Projeler, Türkiye'de Göçmen Sağlığı Hizmetlerinin Desteklenmesi Projesi, 2021 - 2021

DALVA K., BEKSAÇ M., Yükseköğretim Kurumları Destekli Proje, Erken Gebelik Kayıpları ve Yüksek Riskli Gebeliklerin İmmünogenetik Açıdan İncelenmesi, 2017 - 2018

Elçin Y. M., Elçin A. E., Dalva K., TÜBİTAK - AB COST Projesi , 214M159, Pluripotent, Multipotent ve Somatik Hücre Kültürü Temelli Ekstraselüler Matriksin Doğal Niş Olarak ve Doku Mühendisliği İskelesinde Biyomimetik Bileşen Olarak Etkinliğinin Karşılaştırmalı İncelenmesi, 2015 - 2018

DALVA K., BEKSAÇ M., TÜBİTAK Projesi, İnsan Göbek Kordon Kaı Hematopoetik Kök Hücrelerinin Ex Vıvo şartlarda çoğatılması, 2013 - 2017
Elçin Y. M., Parmaksız M., Dalva K., Elçin A. E., Yükseköğretim Kurumları Destekli Proje, 14B0216001, İnsan adipoz kaynaklı mezenkimal kök hücrelerin damar düz kas hücrelerine farklılaşmasının moleküler düzeyde incelenmesi, 2014 - 2016
DALVA K., Yükseköğretim Kurumları Destekli Proje, Ankara Üniversitesi Kordon Kanı ve Kök Hücre Bankası Hizmet ve alt yapı devemlılılığı projesi, 2011 - 2015
DALVA K., BEKSAÇ M., TÜBİTAK Projesi, Multiple Myeloma Plazma Hücre Kanseri nin Spektrometrik ve Spektroskopik Yöntemler ile Araştırılması, 2012 - 2013

Bilimsel Hakemlikler

TURKISH JOURNAL OF HAEMATOLOGY, SCI-E Kapsamındaki Dergi, Aralık 2023
TURKISH JOURNAL OF HAEMATOLOGY, SCI-E Kapsamındaki Dergi, Kasım 2023
FRONTIERS IN GENETICS, SCI-E Kapsamındaki Dergi, Temmuz 2022

Metrikler

Yayın: 267
Atıf (WoS): 1193
Atıf (Scopus): 1574
H-İndeks (WoS): 13
H-İndeks (Scopus): 15